tarlatamab + YL201 + durvalumab

This is an experimental **combination therapy** consisting of three agents: - **Tarlatamab**, a bispecific T-cell engager monoclonal antibody approved for extensive-stage small cell lung cancer (ES-SCLC). It targets delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, redirecting T cells to cancer cells for targeted cytotoxicity. - **YL201** is an investigational agent with limited publicly available mechanistic data, but it is under clinical study in combination with tarlatamab for lung cancer. - **Durvalumab** is a monoclonal antibody acting as a checkpoint inhibitor by targeting programmed death ligand 1 (PD-L1), preventing immune evasion by tumor cells and augmenting anti-tumor immunity. The combination (currently in clinical trial DeLLphi-310 and related studies), is being developed as an immunotherapy for ES-SCLC post-platinum chemotherapy, with a primary focus on safety, tolerability, and preliminary efficacy[3][6][9].

Other names

tarlatamab-dlle